|
Patient number (hospital)
|
Previously treated case
|
Mutations conferring resistance to
|
|---|
|
INH
|
RMP
|
FLQ
|
AG/CP
|
EMB
|
|---|
|
425 (LP)
|
No
|
katG S315T
|
-
|
-
|
-
|
-
|
|
inhA C15T
|
|
472 (TK)
|
No
|
inhA C15T
|
-
|
-
|
-
|
-
|
|
977 (MV)
|
No
|
katG S315T
|
-
|
-
|
-
|
-
|
|
454 (MV)
|
Yes
|
katG S315T
|
-
|
-
|
-
|
-
|
|
446 (LP)
|
No
|
inhA C15T
|
-
|
-
|
rrs C1402T
|
-
|
|
480 (TK)
|
No
|
katG S315T
|
-
|
-
|
rrs C1402T
|
-
|
|
165 (LP)
|
Yes
|
katG deleted
|
-
|
-
|
rrs C1402T
|
-
|
|
175 (TK)
|
Yes
|
katG S315T
|
rpoB H526Y
|
gyrA A90V
|
rrs C1402T
|
embB M306V
|
|
Total
|
8
|
1
|
1
|
4
|
1
|
-
LP Luang Prabang, MV Mahosot Vientiane, TK Thakhek, INH isionazid, RMP rifampycin, FLQ fluoroquinolones, AG/CP aminoglycosides, cyclic peptides, EMB ethambutol.
- (−) Presence of all wild type probes and none mutation probe observed.
